FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions concerns medicine, in particular to oncology, and concerns cancer treatment with pegylated liposomal Doxorubicinum (PLD) in a combination with ecteinescidin 743 (ET-743). Versions of the method of treatment, versions of compositions, and also medical sets are offered for this purpose.
EFFECT: maintenance of effective suppression of a cancer tissue at the expense of combined influence of PLD and E-743 at depression of toxic effects.
41 cl, 1 dwg, 9 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
COMBINED APPLICATION OF ECTEINASCIDIN-743 AND PLATINUM-CONTAINING ANTI-TUMOUR COMPOUNDS | 2004 |
|
RU2391101C2 |
COMPOSITION AND UTILIZATION OF ET743 FOR MALIGNANT TUMOR TREATMENT | 2000 |
|
RU2266734C2 |
IMPROVED SCHEME OF USING ANTITUMOR COMPOUND IN CANCER THERAPY | 2002 |
|
RU2306933C2 |
COMBINATION THERAPY WITH AN ANTITUMOR ALKALOID | 2011 |
|
RU2605335C2 |
COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2011 |
|
RU2743643C2 |
COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2018 |
|
RU2757373C2 |
COMBINATION THERAPY WITH ANTICANCER ALKALOID | 2018 |
|
RU2767664C2 |
METHODS FOR TREATMENT OF METASTATIC CANCER TYPES, USING AXL TRAP RECEPTORS | 2018 |
|
RU2785866C2 |
THERAPEUTIC USE OF THE TLR AGONIST AND COMBINED THERAPY | 2011 |
|
RU2603467C2 |
THERAPEUTIC COMBINATIONS CONTAINING ANTI-FOLR1 IMMUNOCONJUGATES | 2016 |
|
RU2749865C2 |
Authors
Dates
2009-06-27—Published
2005-10-26—Filed